Arbutus Biopharma (ABUS) Net Cash Flow (2013 - 2026)
Arbutus Biopharma (ABUS) posted Net Cash Flow of $5.7 million for Q1 2026, up 229.7% sequentially from -$4.4 million in Q4 2025, and up 669.27% YoY from $742000.0 in Q1 2025.
Arbutus Biopharma (ABUS) Net Cash Flow (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Net Cash Flow for 14 years, with the latest figure at $5.7 million in Q1 2026.
- Quarterly Net Cash Flow rose 669.27% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.4 million (down 123.09% YoY) and the FY2025 annual result came in at -$18.3 million, down 281.65% from the prior year.
- Net Cash Flow rose to $5.7 million in Q1 2026 per ABUS's latest filing, from -$4.4 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $19.7 million in Q2 2024 and troughed at -$34.0 million in Q2 2022.
- A 5-year average of -$5.0 million and a median of $315000.0 in 2025 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2026: Net Cash Flow sank 219.9% in 2024, then soared 669.27% in 2026.
- Over 5 years, Net Cash Flow stood at $6.8 million in 2022, then increased by 28.98% to $8.7 million in 2023, then slumped by 48.32% to $4.5 million in 2024, then sank by 197.43% to -$4.4 million in 2025, then surged by 229.7% to $5.7 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $5.7 million, -$4.4 million, and -$15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | -4.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.53 Mn |
| Jun 30, 2026 | -4.53 Mn |
| Mar 31, 2026 | 5.71 Mn |
| Mar 31, 2026 | 5.71 Mn |
| Dec 31, 2025 | -4.40 Mn |
| Dec 31, 2025 | -4.40 Mn |
| Sep 30, 2025 | -14.99 Mn |
| Sep 30, 2025 | -14.99 Mn |
| Jun 30, 2025 | 315,000.00 |
| Jun 30, 2025 | 315,000.00 |
| Mar 31, 2025 | 742,000.00 |
| Mar 31, 2025 | 742,000.00 |
| Dec 31, 2024 | 4.52 Mn |
| Dec 31, 2024 | 4.52 Mn |
| Sep 30, 2024 | -30.95 Mn |
| Sep 30, 2024 | -30.95 Mn |
| Jun 30, 2024 | 19.70 Mn |
| Jun 30, 2024 | 19.70 Mn |
| Mar 31, 2024 | 16.83 Mn |
| Mar 31, 2024 | 16.83 Mn |